Dynavax Reports Second Quarter 2014 Financial Results and Safety and Pharmacodynamic Results for Asthma and Lupus Drug

Dynavax Reports Second Quarter 2014 Financial Results and Safety and 
Pharmacodynamic Results for Asthma and Lupus Drug Candidates 
BERKELEY, CA -- (Marketwired) -- 08/07/14 --  Dynavax Technologies
Corporation (NASDAQ: DVAX) today reported financial results for the
second quarter ended June 30, 2014 and pharmacodynamic and safety
results from clinical studies of its asthma drug candidate partnered
with AstraZeneca and its systemic lupus erythematosus (SLE) drug
candidate partnered with GlaxoSmithKline. 
Second quarter 2014 financial results 
Dynavax had $154.3 million in cash, cash equivalents and marketable
securities as of June 30, 2014. Total operating expenses for the
quarter ended June 30, 2014 of $27.9 million increased by $10.4
million compared to the quarter ended March 31, 2014 as a result of
the initiation of HBV-23 and significant subject enrollment in this
pivotal phase 3 trial during the quarter.  
"We are very pleased with our progress on HBV-23," said Eddie Gray,
Chief Executive Officer of Dynavax. "HEPLISAV-B will, if approved,
provide patients a valuable alternative to currently available
vaccines, and we are committed to bringing this important product to
the market. In parallel, we are developing our pipeline to take full
advantage of our platform and expertise in TLR immune modulation."  
In April 2014, Dynavax initiated HBV-23, a large safety and
immunogenicity study of its investigational adult hepatitis B
vaccine. The study was designed to provide a sufficiently-sized
safety database for the U.S. Food and Drug Administration to complete
its review of the HEPLISAV-B Biologics License Application. It is
being conducted at 40 sites in the U.S. and will include
approximately 8,250 subjects. Dynavax expects that all HBV-23 study
subjects will be enrolled by the end of 2014 and all follow-up visits
will be completed by the fourth quarter of 2015. 
Safety and pharmacodynamic results for asthma and SLE drug candidates 
In a Phase 1 study, 4 weekly doses of a TLR9 agonist, AZD1419, or
placebo were delivered by inhalation to 45 healthy volunteers.
Ascending doses up to 15.4 mg/week for 4 weeks were well tolerated
and no serious adverse events were observed in treated subjects.
Secondary endpoints assessing pharmacodynamics were met, with
dose-dependent induction of interferon-regulated genes in sputum and
blood cells. Based on these results, Dynavax and its collaboration
partner, AstraZeneca, are evaluating protocols for a clinical trial
in patients with asthma.  
In a Phase 1b/2a study, the safety and pharmacodynamics of a
bifunctional TLR7 and TLR9 inhibitor, DV1179, were assessed in 52 SLE
patients screened for elevated expression of interferon-regulated
genes. DV1179 did not meet the primary or secondary pharmacodynamic
endpoints related to reduction in interferon alpha-regulated genes.
Doses up to 60 mg/week for 8 weeks were well tolerated. The most
common adverse events were injection site reactions. GlaxoSmithKline
will review the data package and determine whether to exercise its
option to license DV1179. 
About Dynavax 
Dynavax, a clinical-stage biopharmaceutical company, discovers and
develops novel vaccines and therapeutics in the areas of infectious
and inflammatory diseases and oncology. Dynavax's lead product
candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B
vaccine. For more information visit www.dynavax.com. 
Forward-Looking Statements 
This press release contains "forward-looking" statements, including
expectations for the conduct, timing and sufficiency of an additional
clinical trial for HEPLISAV-B and plans to continue clinical
development of AZD1419. Actual results may differ materially from
those set forth in this press release due to the risks and
uncertainties inherent in our business, including whether successful
clinical and regulatory development and review and approval of
HEPLISAV-B and our process for its manufacture can occur without
significant delay or additional studies; whether our studies and
manufacturing efforts are sufficient to support registration for
commercialization of HEPLISAV-B in either or both of the US and
Europe; the timing for and costs of achieving the size of the safety
database; the results of clinical trials and the impact of those
results on the initiation and completion of subsequent trials and
issues arising in the regulatory process, including whether a US or
European licensure application will be approved; our ability to
obtain additional financing to support the development and
commercialization of HEPLISAV-B and our other operations; possible
claims against us, including enjoining sales of HEPLISAV-B, based on
the patent rights of others; and other risks detailed in the "Risk
Factors" section of our current periodic reports with the SEC. We
undertake no obligation to revise or update information herein to
reflect events or circumstances in the future, even if new
information becomes available. Information on Dynavax's website at
www.dynavax.com is not incorporated by reference in our current
periodic reports with the SEC. 

                      DYNAVAX TECHNOLOGIES CORPORATION                      
                   CONSOLIDATED STATEMENTS OF OPERATIONS                    
                  (In thousands, except per share amounts)                  
                                     Three Months Ended   Six Months Ended  
                                          June 30,            June 30,      
                                     ------------------  ------------------ 
                                       2014      2013      2014      2013   
                                     --------  --------  --------  -------- 
  Collaboration revenue              $  2,031  $  1,356  $  4,404  $  2,239 
  Grant revenue                         1,007     1,395     2,132     2,155 
  Service and license revenue              10       641        10     1,083 
                                     --------  --------  --------  -------- 
Total revenues                          3,048     3,392     6,546     5,477 
Operating expenses:                                                         
  Research and development             23,639    12,805    36,870    26,969 
  General and administrative            4,085     7,636     8,242    16,436 
  Unoccupied facility expense             178         -       255         - 
                                     --------  --------  --------  -------- 
Total operating expenses               27,902    20,441    45,367    43,405 
                                     --------  --------  --------  -------- 
Loss from operations                  (24,854)  (17,049)  (38,821)  (37,928)
Interest income                            55        54       120       126 
Interest expense                            -       (27)        -       (59)
Other income (expense)                     22      (142)       84      (128)
                                     --------  --------  --------  -------- 
Net loss                             $(24,777) $(17,164) $(38,617) $(37,989)
                                     ========  ========  ========  ======== 
Basic and diluted net loss per share $  (0.09) $  (0.09) $  (0.15) $  (0.21)
                                     ========  ========  ========  ======== 
Shares used to compute basic and                                            
 diluted net loss per share           262,861   182,913   262,863   182,934 
                                     ========  ========  ========  ======== 
                      DYNAVAX TECHNOLOGIES CORPORATION                      
                         SELECTED BALANCE SHEET DATA                        
                               (In thousands)                               
                                                    June 30,    December 31,
                                                      2014          2013    
                                                 ------------- -------------
  Cash, cash equivalents and marketable                                     
   securities                                    $     154,313 $     189,376
  Property and equipment, net                            8,789         8,706
  Goodwill                                               2,557         2,579
  Other assets                                           7,806         3,961
                                                 ------------- -------------
Total assets                                     $     173,465 $     204,622
                                                 ============= =============
Liabilities and stockholders'equity                                         
  Deferred revenues                              $       8,294 $       7,298
  Other liabilities                                     14,501        11,030
                                                 ------------- -------------
  Total liabilities                                     22,795        18,328
  Stockholders' equity                                 150,670       186,294
                                                 ------------- -------------
Total liabilities and stockholders' equity       $     173,465 $     204,622
                                                 ============= =============

Michael Ostrach
Chief Business and Principal Financial Officer
Press spacebar to pause and continue. Press esc to stop.